Anika Therapeutics, Inc. (ANIK) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 22.15M USD | Liabilities, Current |
| Cash and equivalents | 38.41M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 29.06M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 28.57M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $22.15M | $38.41M | (m) | $29.06M | $28.57M | (m) |
| 2026-03-31 | $92.56M | $20.97M | $41.02M | $25.77M | $25.77M | $22.84M | 4.41× |
| 2026-01-01 | (m) | (m) | (m) | (m) | $23.70M | (m) | (m) |
| 2025-12-31 | $104.86M | $21.91M | $57.48M | $23.69M | $23.69M | $18.79M | 4.79× |
| 2025-09-30 | $102.36M | $19.09M | $57.99M | $22.19M | $22.19M | $16.28M | 5.36× |
| 2025-06-30 | $101.08M | $16.08M | $53.17M | $23.95M | $23.95M | $16.92M | 6.29× |
| 2025-03-31 | $97.34M | $17.90M | $53.37M | $21.99M | $21.99M | $21.34M | 5.44× |
| 2025-01-01 | (m) | (m) | (m) | (m) | $23.60M | (m) | (m) |
| 2024-12-31 | $102.82M | $23.31M | $55.63M | $23.59M | $23.59M | $23.81M | 4.41× |
| 2024-09-30 | $119.08M | $25.49M | $62.37M | $28.36M | $28.36M | $39.63M | 4.67× |
| 2024-06-30 | $130.37M | $26.12M | $62.82M | $33.77M | $33.77M | $51.46M | 4.99× |
| 2024-03-31 | $132.78M | $28.46M | $68.63M | $32.08M | $32.08M | $49.41M | 4.67× |
| 2023-12-31 | $144.79M | $31.06M | $72.87M | $35.96M | $35.96M | $46.39M | 4.66× |
| 2023-09-30 | $140.01M | $28.06M | $70.65M | $34.68M | $34.68M | $43.72M | 4.99× |
| 2023-06-30 | $138.54M | $23.46M | $65.07M | $36.74M | $36.74M | $42.60M | 5.91× |
| 2023-03-31 | $141.00M | $28.69M | $79.74M | $30.63M | $30.63M | $41.32M | 4.91× |
| 2022-12-31 | $155.58M | $27.91M | $86.33M | $34.63M | $34.63M | $39.77M | 5.57× |
| 2022-12-01 | (m) | (m) | (m) | (m) | $34.63M | (m) | (m) |
| 2022-09-30 | (m) | $26.35M | $87.78M | $34.17M | (m) | $37.24M | (m) |
| 2022-06-30 | (m) | $29.43M | $91.39M | $32.17M | (m) | $35.34M | (m) |
| 2022-03-31 | (m) | $26.99M | $90.33M | $29.31M | (m) | $35.23M | (m) |
| 2021-12-31 | $124.23M | $29.80M | $94.39M | $0.00 | $29.84M | $36.01M | 4.17× |
| 2021-09-30 | (m) | $28.77M | $90.98M | (m) | $32.35M | $35.02M | (m) |
| 2021-06-30 | $126.61M | $41.37M | $97.18M | $0.00 | $29.43M | $42.86M | 3.06× |
| 2021-03-31 | $121.11M | $46.97M | $94.60M | $0.00 | $26.51M | $42.72M | 2.58× |
| 2020-12-31 | $122.42M | $36.87M | $95.82M | $2.50M | $24.10M | $46.21M | 3.32× |
| 2020-09-30 | $147.77M | $31.14M | $104.22M | $20.54M | $23.01M | $47.88M | 4.75× |
| 2020-06-30 | $168.46M | $27.91M | $116.75M | $27.62M | $24.09M | $46.48M | 6.04× |
| 2020-03-31 | $120.39M | $26.19M | $65.83M | $26.45M | $28.10M | $35.08M | 4.60× |
| 2019-12-31 | $208.02M | $16.28M | $157.46M | $27.48M | $23.08M | $22.00M | 12.78× |
| 2019-09-30 | $197.09M | $11.20M | $103.38M | $69.83M | $23.89M | $25.24M | 17.61× |
| 2019-06-30 | $164.53M | $10.39M | $69.41M | $72.05M | $23.07M | $22.99M | 15.84× |
| 2019-03-31 | $185.00M | $11.60M | $95.51M | $71.22M | $18.27M | $22.62M | 15.95× |
| 2018-12-31 | $179.79M | $11.29M | $89.04M | $69.97M | $20.77M | $21.30M | 15.93× |
| 2018-09-30 | $169.78M | $9.30M | $81.83M | $67.19M | $20.77M | $23.83M | 18.25× |
| 2018-06-30 | $162.69M | $12.53M | $126.05M | $13.25M | $23.39M | $24.06M | 12.98× |
| 2018-03-31 | $181.34M | $14.12M | $141.80M | $21.25M | $18.29M | $22.77M | 12.84× |
| 2017-12-31 | $181.08M | $13.07M | $133.26M | $24.00M | $23.82M | $22.04M | 13.85× |
| 2017-09-30 | $176.51M | $11.71M | $126.96M | $25.75M | $23.80M | $20.25M | 15.08× |
| 2017-06-30 | $173.32M | $13.44M | $117.87M | $25.00M | $30.45M | $17.58M | 12.90× |
| 2017-03-31 | $159.70M | $10.22M | $119.37M | $19.25M | $21.08M | $16.18M | 15.63× |
| 2016-12-31 | $152.36M | $8.80M | $104.26M | $20.50M | $27.60M | $15.98M | 17.32× |
| 2016-09-30 | $142.13M | $7.59M | $98.05M | $22.25M | $21.83M | $18.02M | 18.73× |
| 2016-06-30 | $136.22M | $10.52M | $89.13M | $22.50M | $24.60M | $17.26M | 12.95× |
| 2016-03-31 | $130.63M | $10.87M | $92.84M | $23.00M | $14.80M | $15.77M | 12.02× |
| 2015-12-31 | $160.11M | $17.28M | $110.71M | $27.75M | $21.65M | $14.94M | 9.27× |
| 2015-09-30 | $153.85M | $13.24M | $108.47M | $22.01M | $23.38M | $12.08M | 11.62× |
| 2015-06-30 | $141.60M | $7.96M | $103.92M | $18.51M | $19.17M | $11.72M | 17.79× |
| 2015-03-31 | $128.33M | $6.16M | $99.80M | $12.50M | $16.03M | $12.52M | 20.84× |
| 2014-12-31 | $124.06M | $5.97M | $100.16M | $6.75M | $17.15M | $12.41M | 20.77× |
| 2014-09-30 | $111.94M | $6.43M | $71.77M | $20.00M | $20.17M | $13.58M | 17.40× |
| 2014-06-30 | (m) | $7.32M | $84.88M | (m) | $19.24M | $13.86M | (m) |
| 2014-03-31 | (m) | $7.71M | $82.16M | (m) | $16.47M | $12.98M | (m) |
| 2013-12-31 | (m) | $9.28M | $63.33M | (m) | $18.74M | $11.00M | (m) |
| 2013-09-30 | (m) | $10.36M | $64.06M | (m) | $16.50M | $11.58M | (m) |
| 2013-06-30 | (m) | $11.70M | $54.14M | (m) | $19.07M | $10.36M | (m) |
| 2013-03-31 | (m) | $10.74M | $50.97M | (m) | $14.78M | $9.95M | (m) |
| 2012-12-31 | (m) | $14.45M | $44.07M | (m) | $21.46M | $8.28M | (m) |
| 2012-09-30 | (m) | $12.15M | $39.86M | (m) | $16.34M | $8.93M | (m) |
| 2012-06-30 | (m) | $15.21M | $37.91M | (m) | $17.69M | $10.78M | (m) |
| 2012-03-31 | (m) | $12.88M | $34.00M | (m) | $17.00M | $9.08M | (m) |
| 2011-12-31 | (m) | $14.54M | $35.78M | (m) | $17.31M | $7.30M | (m) |
| 2011-09-30 | (m) | $15.14M | $29.05M | (m) | $17.73M | $7.87M | (m) |
| 2011-06-30 | (m) | $17.38M | $26.83M | (m) | $17.02M | $9.17M | (m) |
| 2011-03-31 | (m) | (m) | $29.08M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $19.37M | $28.20M | (m) | $14.82M | $8.95M | (m) |
| 2010-09-30 | (m) | (m) | $25.77M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $23.65M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $24.43M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $43.19M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |